Corpus Intelligence IC Memo — DEL AMO HOSPITAL 2026-04-26 12:47 UTC
IC Memo — DEL AMO HOSPITAL
Investment Committee Memorandum | CA | 166 beds | Grade C | EBITDA uplift $3.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DEL AMO HOSPITAL

CCN 054053 | nan, CA | 166 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DEL AMO HOSPITAL is a 166-bed safety-net/medicaid heavy in nan, CA with $52.9M in net patient revenue and a 24.3% operating margin. The hospital serves a payer mix of 12.0% Medicare, 40.3% Medicaid, and 47.7% commercial.

Thesis: Turnaround. Our ML models identify $3.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 24.3% to 31.7% (+736bps).

Net Revenue HCRIS$52.9M
Current EBITDA COMPUTED$12.9M
Operating Margin COMPUTED24.3%
Occupancy HCRIS82.7%
Revenue / Bed COMPUTED$319K
Net-to-Gross HCRIS53.1%
Distress Probability ML53.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
208
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 24.3% places it above the state median. Among 208 size-comparable peers (83-332 beds), the median margin is -4.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (83-332), prioritizing same-state peers. 208 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DEL AMO HOSPITAL (Target)CA166$52.9M24.3%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
KECK HOSPITAL OF USCCA301$1.11B-20.8%
SUTTER ROSEVILLE MEDICAL CENTECA318$1.07B12.1%
CALIFORNIA PACIFIC MEDICAL CENCA274$987.8M-18.5%
ZUCKERBERG SAN FRANCISCO GENERCA284$889.5M-41.7%
SANTA MONICA UCLA MEDICAL CENTCA281$835.9M2.8%
ENLOE MEDICAL CENTERCA258$834.4M-0.5%
KFH - SOUTH SACRAMENTOCA233$803.9M5.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$644K+122bp9mo
Clean Claim Rate88.0%96.0%$34K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.1M
Denial Rate Reduction
$1.0M
A/R Days Reduction
$644K
Clean Claim Rate
$34K
Total EBITDA Uplift$3.9M
Current EBITDA$12.9M
+ RCM Uplift+$3.9M
Pro Forma EBITDA$16.8M
Current Margin24.3%
Pro Forma Margin31.7%
WC Released (1x)$2.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$19.8M$123.8M6.25x44.3%
Base (11x exit)10.0x11.0x$19.8M$142.6M7.20x48.4%
Bull Case9.0x11.0x$17.8M$161.9M9.09x55.5%
Bull (12x exit)9.0x12.0x$17.8M$181.9M10.21x59.2%
Bear Case11.0x10.0x$21.8M$97.9M4.50x35.1%
Bear (11x exit)11.0x11.0x$21.8M$114.8M5.27x39.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (40.3%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 53.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 208 hospitals with 83-332 beds
  • Same-state prioritization (n=209)
  • Comp margins: P25=-17.1% / P50=-4.5% / P75=3.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.